Investigational Oral Microbiome Therapeutic SER-109 and Quality-of-Life in Recurrent C difficile

United Kingdom News News

Investigational Oral Microbiome Therapeutic SER-109 and Quality-of-Life in Recurrent C difficile
United Kingdom Latest News,United Kingdom Headlines
  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 51%

New live bacterial product for stubborn superbug improves quality of life jamanetworkopen

Kevin W. Garey, PharmD, MS, Professor and Chair, University of Houston, 4349 Martin Luther King Blvd, Houston, TX 77204 .Dr Garey had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Acquisition, analysis, or interpretation of data:

Garey, Jo, Gonzales-Luna, Lapin, Deshpande, Wang, Hasson, Huang, Ray Reese, Wu, Hohmann, Feuerstadt, Oneto, Berenson, McGovern, von Moltke.Critical revision of the manuscript for important intellectual content: Garey, Jo, Gonzales-Luna, Lapin, Deshpande, Wang, Hasson, Pham, Huang, Ray Reese, Wu, Hohmann, Feuerstadt, Oneto, Berenson, Lee, von Moltke.Administrative, technical, or material support:Conflict of Interest Disclosures:

Dr Garey reported receiving grants from Seres Therapeutics during the conduct of the study and receiving grants from Summit, Acurx Pharmaceuticals, and Paratek Pharmaceuticals outside the submitted work. Dr Gonzales-Luna reported receiving grants from Seres Therapeutics during the conduct of the study. Dr Lapin reported receiving grants from Seres Therapeutics during the conduct of the study.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

medical_xpress /  🏆 101. in UK

United Kingdom Latest News, United Kingdom Headlines



Render Time: 2025-02-15 03:43:51